← Russell 3000 cross-section

TRDA Entrada Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$275m
Revenue TTM
$5m
Net income TTM
$-166m
Free cash flow
$-134m
Composite score
27.0
Sector rank
#2719

Valuation

P / E
EV / EBITDA
EV / sales
37.6
FCF yield
-48.80%
Earnings yield vs 10-yr
-64.96pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-3,537.7%
EBITDA margin
-3,688.3%
ROE
-71.0%
ROIC
-131.6%
Revenue growth
-94.1%

Insider activity, last 90 days

Net open-market
$-4.05m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.